Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma
- 12 February 2010
- journal article
- research article
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 99 (2) , 237-242
Abstract
After withdrawal of bevacizumab in patients with recurrent high-grade glioma, we have observed a rapid tumour re-growth or “rebound” radiographic phenomenon with accelerated clinical decline. We retrospectively reviewed 11 patients treated at the Henry Ford Hermelin Brain Tumor Center with recurrent high-grade glioma who demonstrated a rebound progression pattern after the discontinuation of bevacizumab. The original tumour area-of-enhancement increased by a mean of 158%, when compared to the rebound magnetic resonance imaging. After rebound, no patients (0/8) showed a response to next-line treatments that did not include bevacizumab. The median survival of those re-treated with bevacizumab was 149 and 32 days for those who received other regimens. Abrupt discontinuation of bevacizumab after recurrence often leads to a dramatic rebound phenomenon and rapid clinical decline. Slow tapering of the bevacizumab dose after tumour progression may prevent this from occurring and improve responsiveness to next-line therapies.Keywords
This publication has 19 references indexed in Scilit:
- Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast CancerNew England Journal of Medicine, 2007
- Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung CancerNew England Journal of Medicine, 2006
- Mechanisms of angiogenesis in gliomasJournal of Neuro-Oncology, 2006
- Expression of Vascular Endothelial Growth Factor (VEGF) and VEGF Receptors in Tumor Angiogenesis and MalignanciesIntegrative Cancer Therapies, 2005
- VEGF as a Therapeutic Target in CancerOncology, 2005
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal CancerNew England Journal of Medicine, 2004
- A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal CancerNew England Journal of Medicine, 2003
- Clinical Implications of Circulating Angiogenic Factors in Cancer PatientsJournal of Clinical Oncology, 2001
- Outcomes and Prognostic Factors in Recurrent Glioma Patients Enrolled Onto Phase II Clinical TrialsJournal of Clinical Oncology, 1999